Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 3/20 | 0.69 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.69 |
| ▸ | LGALS4 | P56470 | 2/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | B4GALT1 | P15291 | 1/20 | 0.45 |
| ▸ | CD69 | Q07108 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10060391 | 0.99 | LGALS3 (0.71) | LGALS3LGALS8LGALS4MAPK1MEN1 | |
| SCHEMBL10026220 | 0.99 | LGALS3 (0.71) | LGALS3LGALS8LGALS4MAPK1MEN1 | |
| SCHEMBL19475940 | 0.92 | MAPK1 (0.65) | LGALS3LGALS8LGALS4MAPK1MEN1 | |
| SCHEMBL18828676 | 0.92 | MAPK1 (0.65) | LGALS3LGALS8LGALS4MAPK1MEN1 | |
| SCHEMBL2482720 | 0.92 | LGALS8 (0.80) | LGALS3LGALS8LGALS4MAPK1MEN1 | |
| SCHEMBL12715191 | 0.92 | LGALS8 (0.80) | LGALS3LGALS8LGALS4MAPK1MEN1 | |
| SCHEMBL12715043 | 0.92 | LGALS8 (0.80) | LGALS3LGALS8LGALS4MAPK1MEN1 | |
| SCHEMBL14355286 | 0.92 | LGALS8 (0.80) | LGALS3LGALS8LGALS4MAPK1MEN1 | |
| SCHEMBL18962223 | 0.92 | MAPK1 (0.72) | LGALS3LGALS8LGALS4MAPK1MEN1 | |
| SCHEMBL13736745 | 0.90 | LGALS3 (0.87) | LGALS3LGALS8LGALS4MAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090206245-A1 | Mass analysis method using fine metal particles | SHIONOGI CO., LTD (JP) | 2009-08-20 | — | — | US | disclosed |
| US-20090206245-A1 | Mass analysis method using fine metal particles | SHIONOGI CO., LTD (JP) | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090206245-A1 | Mass analysis method using fine metal particles | OSTC, ZKSCAN2, SLC17A5 | LGALS3 206/4885LGALS8 733/4885LGALS4 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.